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This study was undertaken to investigate the expression and predictive value for outcome of multidrug resistance-associated (MDR)
proteins P-glycoprotein (Pgp), MRP1, BCRP, and LRP, in advanced testicular germ-cell tumours (TGCT). Paraffin-embedded sections
from 56 previously untreated patients with metastatic TGCT were immunostained for Pgp, MRP1, BCRP, and LRP. All patients
received platinum-based chemotherapy after orchidectomy. Immunostaining was related to clinicopathological parameters, response
to chemotherapy, and outcome. Strong and intermediate expressions of the different MDR-related proteins were: 27 and 41% (Pgp),
54 and 37% (MRP1), 86 and 7% (BCRP), and 14 and 29% (LRP). P-glycoprotein and MRP1 associated, respectively, to low AFP
(P¼ 0.026) and high LDH levels (P¼ 0.014), whereas LRP expression associated with high b-hCG levels (P¼ 0.003) and stage IV
tumours (P¼ 0.029). No correlation was found between Pgp, MRP1, and BCRP expression and response to chemotherapy and
survival. In contrast, patients with LRP-positive tumours (strong or intermediate expression) had shorter progression-free
(P¼ 0.0006) and overall survival (P¼ 0.0116) than LRP-negative patients, even after individual log-rank adjustments by statistically
associated variables. Our data suggest that a positive LRP immunostaining at the time of diagnosis in metastatic TGCT is associated
with an adverse clinical outcome.
British Journal of Cancer (2003) 88, 879–886. doi:10.1038/sj.bjc.6600803 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: testicular germ-cell tumours; lung resistance-related protein; P-glycoprotein; multidrug resistance-associated protein 1;
breast cancer resistance protein; multidrug resistance























































Current use of cisplatin-based chemotherapy and surgery in the
first-line treatment of advanced testicular germ-cell tumours
(TGCT) results in long-term disease-free status in about 80%
of cases (Bosl and Motzer, 1997; Horwich et al, 1998). As a result of
the high cure rate and the morbidity of treatment, clinical research
has focused on optimising the management of this disease,
tailoring therapies according to the risk of failure of the individual
patient (Bosl and Motzer, 1997; Sonneveld et al, 2001). Factors
associated with a poor-outcome have been analysed in several
large studies, and include the extent of metastatic disease and
serum levels of the b-subunit of human chorionic gonadotropin
(b-hCG), a-fetoprotein (AFP) and lactate dehydrogenase (LDH)
(Germa`-Lluch et al, 1980; Mead et al, 1992). The most recent and
commonly employed prognostic model for disseminated disease is
the International Germ Cell Consensus Classification (IGCCC),
which predicts relapse at 5 years for 12, 25, and 59% patients in the
good, intermediate, and poor prognosis groups, respectively
(International Germ Cell Cancer Collaborative Group, 1997).
Treatment failure in this disease is closely related to inherent or
developed resistance to chemotherapy (Bosl and Motzer, 1997).
Patients with refractory disease, failing to respond to initial
treatment, have a worse prognosis (Motzer et al, 1991). However,
current knowledge of the molecular determinants of chemoresis-
tance involved in TGCT is only marginal (Houldsworth et al, 1998;
Rao et al, 1998; Kersemaekers et al, 2002).
In particular, little is known about clinical multidrug resistance
(MDR) in TGCT (Van Brussel and Mickisch, 1998). Multidrug
resistance consists of de novo or acquired cross-resistance to
structurally and functionally unrelated drugs, some of them
relevant in the treatment of TGCT such as Vinca alkaloids,
epipodophyllotoxins and anthracyclines (Lehnert, 1996). Among
the various molecular mechanisms associated with MDR in
experimental tumour models, one of the most extensively studied
involves decreased drug accumulation due to enhanced efflux by
ATP-dependent transporter proteins such as P-glycoprotein (Pgp),
the human multidrug resistance-associated protein 1 (MRP1), and
the recently described breast cancer resistance protein (BCRP).
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P-glycoprotein overexpression is associated with resistance to
natural product drugs, including anthracyclines, etoposide,
vincristine and vinblastine, and paclitaxel (Germann, 1996).
Multidrug resistance-associated protein 1 is overexpressed in
many non-Pgp-mediated MDR cell lines, conferring in vitro
resistance, among others, to etoposide, vincristine, vinblastine,
and to methotrexate after short-term exposure (Borst et al, 2000).
Breast cancer resistance protein is a newly described transporter,
isolated from mitoxantrone-selected MDR cell lines not expressing
Pgp or MRP (Allikmets et al, 1998; Doyle et al, 1998). Breast cancer
resistance protein is associated with cross-resistance to dauno- and
doxorubicin, mitoxantrone, and camptothecins (Maliepaard et al,
1999).
Another protein related to an MDR-phenotype is the lung
resistance-related protein (LRP) (Scheper et al, 1993). Lung
resistance-related protein has been identified as the human major
vault protein (MVP), the principal constituent of the complex
ribonucleoprotein particles known as vaults (Scheffer et al, 1995).
Of interest in TGCT, LRP/vaults have been associated with in vitro
resistance to drugs such as etoposide, doxorubicin, vincristine,
and paclitaxel, but also to nonclassical MDR drugs such as cis-
platin and carboplatin (Izquierdo et al, 1996a; Kitazono et al,
1999). Although the function of vaults in both normal and cancer
cells is not fully elucidated, they are thought to be involved in
intracellular redistribution of drugs, reducing exposure of nuclear
targets from cytotoxic agents (Chugani et al, 1993; Kitazono et al,
1999).
We undertook the present study to assess the immunohisto-
chemical expression of the MDR-related proteins Pgp, MRP1,
BCRP, and LRP in advanced TGCT, and to determine whether such
expression is related to response to first-line chemotherapy and
survival.
PATIENTS AND METHODS
The expression of MDR-related proteins Pgp, MRP1, BCRP, and
LRP was studied in paraffin-embedded samples from patients with
advanced TGCT. This expression was retrospectively correlated
with clinical and pathological characteristics of the patients,
response to chemotherapy, and outcome.
Sample selection
Between March 1990 and February 2001, 65 patients with primary
advanced TGCT were treated in our institution. We studied
banked samples from 56 specimens, corresponding to previously
untreated patients undergoing orchidectomy for diagnostic
evaluation and treatment. Samples were obtained from the
Department of Pathology at the Ciutat Sanita`ria i Universita`ria
de Bellvitge, Barcelona, Spain. Eligible patients were those with
advanced disease (stage I excluded) undergoing induction
chemotherapy, and with available material. The histological
diagnosis was based on conventional morphologic examination
of paraffin sections, following World Health Organization criteria
(Mostofi and Sesterhenn, 1998).
Treatment, evaluation of response, and survival
All patients were primarily treated with inguinal orchidectomy and
postoperative cisplatin-based induction chemotherapy. Immedi-
ately after conventional induction chemotherapy, seven poor-risk
patients (IGCCC) received high-dose chemotherapy as consolida-
tion treatment. Complete responders to chemotherapy (CR)
were patients with normalisation of serum tumour markers and
no clinical or radiological evidence of residual masses, or absence
of viable cancer cells such as seminoma, embryonal carcinoma
(EC), immature teratoma, yolk sac tumour (YS), choriocarcinoma
(CC), and syncytiotrophoblastic cells in completely resected
residual masses (mature teratoma (MT) was not considered
malignant component). Complete responders to chemotherapy
plus surgery (CR-S) were those with viable malignant cells in
completely resected residual masses. Incomplete responders (IR)
were patients with persisting elevation of tumour markers,
incomplete surgical resection of residual disease, or disease
progression while receiving chemotherapy or within 1 month after
the completion of chemotherapy. Events in the progression-free
survival (PFS) analysis were: incomplete response, and relapse
(rising tumour markers and/or an increase in tumour volume,
unless caused by completely resectable MT). Patients in progres-
sion were managed with a variety of second-line chemotherapy
regimens and surgery if appropriate. Only deaths related to TGCT
progression were considered as events for overall survival (OS)
analysis.
Monoclonal antibodies
The IgG1 murine monoclonal antibody (MAb) JSB-1 was used for
Pgp detection in a concentration of 50mg ml1 in phosphate-
buffered saline (PBS) plus 1% bovine serum albumin (BSA, Sigma,
St Louis, MO, USA). For MRP1, the IgG2a MAb MRPm5 was used
in a concentration of 5 mg ml1 in 1% PBS/BSA. For BCRP, the
newly described IgG2a MAb BXP-21 was used in a concentration of
25mg ml1 in 1% PBS/BSA. JSB-1, MRPm5, and BXP-21 were
obtained from the Department of Pathology, Free University
Hospital, Amsterdam, the Netherlands (Scheper et al, 1988; Flens
et al, 1994; Maliepaard et al, 2001). None of these three MAbs cross
react with the other MDR proteins (Maliepaard et al, 2001). Finally,
the IgG1 murine MAb LRP (Transduction Labs, Los Angeles, CA,
USA) was used for detection of LRP in a concentration of
2.5mg ml1 in 1% PBS/BSA.
Immunohistochemistry
Immunohistochemistry was performed on 4 mm formalin-fixed,
paraffin-embedded sections mounted on poly-L-lysin-coated glass
microslides, and dried at 371C O/N. The immunoperoxidase
reaction conditions used for each MAb were selected on the basis
of previous optimisation of the immunohistochemical protocols.
After conventional deparaffination and rehydration, endogenous
peroxidase activity was quenched by incubation in 3% H2O2
(10 min) at room temperature. Pretreatment in a pressure cooker
(20 min) with either citrate buffer (10 mM citric acid pH 6.0 in
distilled water) for MRPm5, LRP, and BXP-21, or EDTA (1 mM) for
JSB-1 was performed to unmask epitopes. Next, samples were
incubated (30 min) in normal rabbit serum (1 : 50 in 1% PBS/BSA),
and then with the optimally diluted specific antibody (60 min) at
room temperature in a humidified chamber. The MAb BXP-21 was
detected by the Dako EnVisionTM+System-horseradish peroxidase
(Dako Corp., Glostrup, Denmark) for 30 min (Diestra et al, 2002).
A rabbit anti-mouse biotin-conjugated (1 : 150 for 30 min, Zymed
Labs, San Francisco, CA, USA) followed by a streptavidin –
horseradish peroxidase (1 : 500 for 1 h, Zymed) method was used
for MAbs MRPm5 and LRP. JSB-1 was developed by a twice-each
alternating incubation with a rabbit anti-mouse biotin-conjugated
method (1 : 500 for 30 min, Dako) followed by a streptavidin –
biotin complex (1 : 200 for 1 h, Dako). Staining with an irrelevant
IgG or an isotype-specific antibody was routinely performed as a
negative control procedure in the normal tissues and in all the
clinical samples. Bound peroxidase was developed with 3,30-
diaminobenzidine (Sigma).
As positive control tissues for the immunohistochemical assays,
liver was used for JSB-1 (Van der Valk et al, 1990), colon for
MRPm5 (Flens et al, 1996) and LRP (Izquierdo et al, 1996b), and
placenta for BXP-21 (Maliepaard et al, 2001). All slides were
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examined and scored by two independent observers (EC and AZ)
blinded to the clinical data. Tumour cells were identified on
morphological criteria. The MDR proteins were studied in adjacent
slides from the most representative paraffin block available for
each specimen. Only viable malignant germ cells (excluding MT
elements) were considered for evaluation. By prior agreement, in
accordance with previous literature, sections were evaluated in a
semi quantitative way taking into account the percentage and
intensity of staining of tumour cells (Baldini et al, 1995; Izquierdo
et al, 1995; Arts et al, 1999; Eid et al, 2000). Three staining
categories were established: negative (no staining), intermediate
(positive staining in p10% of tumour cells or weak and diffuse
positive staining), and strong (moderate/strong staining in 410%
of tumour cells). A priori, it was planned that the intermediate
category needed to be grouped with either the negative or the
strong category for statistical correlations (see below). The reasons
for this were: (1) to ascertain whether the intermediate category
provided more predictive information for each protein when
grouped with any of the other two categories; (2) to perform
meaningful statistical analysis with only two groups because of the
limited number of patients; (3) a clinical relevant cut-off level of
expression of MDR proteins is not well defined yet and it may be
different for each protein and each tumour type. Intensity and
pattern of staining on the different histological subtypes in each
sample were recorded separately.
Statistical analysis
Clinicopathological characteristics were determined previous to
chemotherapy. These characteristics and response rates to
induction chemotherapy were retrospectively assessed for their
relation with Pgp, MRP1, BCRP, and LRP expression, using w2 or
the Fisher’s exact two-tailed test as appropriate. For survival
analysis, follow-up started the date of the first cycle of induction
chemotherapy. Univariate survival analysis curves were generated
using the Kaplan – Meier method and compared using the log-
rank test (Kaplan and Meier, 1958; Mantel, 1966). A stratified
Mantel – Haenszel test was performed to compare survival curves
in order to adjust for the potential confounding effect of
statistically associated variables upon differences between groups.
Hypotheses were evaluated at a two-sided significance level of 0.05.
The SPSS package (SPSS Inc, Chicago, IL, USA) was used for
calculations.
RESULTS
Clinical and pathological characteristics, response to
chemotherapy, and outcome
The median age at initial orchidectomy was 24 years (range, 16– 56
years). No patient had a previous history of cancer, except for one
(2%) having a contralateral and successfully treated TGCT more
than 9 years before. The characteristics of the 56 patients included
in the study are summarised in Table 1 (left column). The 52 non-
seminomatous TGCT included: 41 mixed tumours, seven EC, three
YS, and one CC. Thirty-five (62%) were good-risk patients,
11 (20%) intermediate-risk, and 10 (18%) poor-risk, according to
the IGCCC criteria (International Germ Cell Cancer Collabor-
ative Group, 1997). Chemotherapy regimens used (Germa`-Lluch
et al, 1999) are listed in Table 2. Median number of cycles was
4 (range, 2–8). One patient (2%) was excluded from the analysis
of response to chemotherapy because of a nonrelated-to-cancer
death during treatment. Therefore, 55 patients were evaluable
for tumour response to induction chemotherapy. Fifty-one
CR (93%), three CR-S (5%), and one IR (2%) to first-line
chemotherapy were accounted. Among those achieving a CR, 16
underwent surgery of residual masses: six showed either necrosis
or fibrosis and 10 MT only. One of the CR-S patients actually
progressed to first-line chemotherapy but underwent complete
salvage surgery and continues relapse-free with more than 4 years
of follow-up.
Table 1 Clinical and pathological characteristics according to Pgp, MRP1, BCRP, and LRP expression
No. (%) Pgp+(%)a MRP1+(%)a BCRP+(%)a LRP+(%)a
All cases 56(1 0 0) 15(27) 30(54) 48(86) 24(43)
Histology
Nonseminoma 52(93) 13(25) 27(52) 46(88.5) 23(44)
Seminoma 4(7) 2(50) 3(75) 2(50) 1(25)
Stage (Royal Marsden)
IM+II – III 39(70) 12(31) 20(51) 32(82) 13(33)
IV 17(30) 3(18) 10(59) 16(94) 11(65)***
Pre-CT serum TM
AFP
p1000 ng ml1 45(80) 15(33)* 23(51) 39(87) 19(42)
>1000 ng ml1 11(20) 0(0) 7(64) 9(82) 5(45.5)
b-hCG
p5000 IU l1 47(84) 13(28) 24(51) 40(85) 16(34)
>5000 IU l1 9(16) 2(22) 6(67) 8(89) 8(89)****
LDH
p1.5 upper N thresh 46(82) 13(28) 21(46) 39(85) 19(41)
>1.5 upper N thresh 10(18) 2(20) 9(90)** 9(90) 5(50)
IGCCC
Good 35(62.5) 11(31) 16(46) 30(86) 13(37)
Intermediate or poor 21(37.5) 4(19) 14(67) 18(86) 11(52)
Vascular invasion
Yes 38(68) 12(32) 22(58) 34(89) 17(45)
No 18(32) 3(17) 8(44) 14(78) 7(39)
CT=chemotherapy, N thresh=normal threshold, TM=tumour markers. aPgp+, MRP1+, and BCRP+ represent
immunohistochemical category strong; LRP+ represents the grouping of categories intermediate and strong (see Patients
and Methods, and Results). *P=0.026 (Fisher’s exact test). **P=0.014 (Fisher’s exact test). ***P=0.029 (w2 test).
****P=0.003 (Fisher’s exact test).
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The median follow-up was 49.5 months (range 2 –111 months).
Seven patients (12.5%) progressed to first-line treatment, including
1 IR and 6 relapses. Four patients (7%) died of TGCT and two (4%)
of non-TGCT-related reasons (second carcinoma and intracranial
haemorrhage).
Pgp, MRP1, BCRP, and LRP expression in TGCT at
diagnosis
The results of immunohistochemistry are summarised in Table 3.
Fifteen (27%) and 23 (41%) of the 56 specimens showed strong and
intermediate expression of Pgp, respectively. The staining pattern
was diffuse and homogeneous, cytoplasmic and occasionally
membranous. Thirty (54%) and 21 (37%) of the 56 cases displayed
strong and intermediate expression of MRP1, respectively. Im-
munostaining was rather heterogeneous. MRP1 was detected at the
cytoplasm, although nuclear and scarce membranous expressions
were also found. For both Pgp and MRP1, the intermediate category
was composed mainly of samples with a weak expression in over
10% of tumour cells (20 out of 23 and 17 out of 21, respectively).
Forty-eight (86%) and four (7%) of the 56 cases displayed,
respectively, strong and intermediate expression of BCRP, with a
mixed staining pattern, membranous (particularly among EC and
YS elements) and cytoplasmic (in syncytiotrophoblasts). BCRP
staining intensity was mostly strong and rather homogeneous as
shown in Figure 1A, except for YS elements (usually positive in
areas with epithelial differentiation and negative where mesench-
ymal). Eight (14%) and 16 (29%) of the 56 cases displayed,
respectively, strong and intermediate expression of LRP, with a
typical granular cytoplasmic pattern as shown in Figure 1B
(Izquierdo et al, 1996b). Intensity was mostly strong and
heterogeneous, with the exception of syncytiotrophoblastic areas,
which showed homogeneous staining. Remarkably, 15 of 16 samples
in the intermediate category had less than 10% intense positive
cells. In eight of these 15, one histological subtype (six CC and
two immature teratomas) with a minor overall representation
(p10%) was found universally positive. No staining was observed
among negative controls for all four MAbs. No correlation was
found between the expressions of the different proteins (data
not shown).
MDR status and established prognostic factors
For the reasons described before (see Patients and Methods),
the intermediate immunohistochemical category was grouped
either with the negative or the strong category for statistical
correlations with other prognostic factors and analysis of out-
come. Table 1 summarises these correlations. Tumours with
strong expression of Pgp were more frequently observed in
patients with AFP levels o1000 ng ml1 (P¼ 0.026). Tumours
with strong expression of MRP1 correlated with LDH levels
41.5 upper normal threshold (P¼ 0.014). No association could be
identified for BCRP. Tumours with strong or intermediate
expression of LRP associated with b-hCG levels 45000 IU/l1
(P¼ 0.003) and stage IV (P¼ 0.029) according to the Royal
Marsden Hospital (RMH) Classification (Peckham et al, 1979).
Table 2 First-line chemotherapy regimens
Patients (N=56)
Regimens No. %
BEPa 37 66
BOMP-EPI 16 29
EP 2 4
Other platinum based 1 1
High doseb 7 13
BEP=etoposide, cisplatin, bleomycin, EP=etoposide, cisplatin, BOMP-EPI=bleomycin,
vincristine, methotrexate, cisplatin/etoposide, ifosfamide, cisplatin. aIncludes one
patient nonassessable for response. bImmediately after conventional induction
chemotherapy, seven poor-risk patients (IGCCC) received high-dose chemotherapy
as consolidation treatment.
Table 3 Pgp, MRP1, BCRP, and LRP expressions in testicular germ-cell
tumours at diagnosis
Category Stronga Intermediatea Negativea
Pgp 15 (27%) 23 (41%) 18 (32%)
MRP1 30 (54%) 21 (37%) 5 (9%)
BCRP 48 (86%) 4 (7%) 4 (7%)
LRP 8 (14%) 16 (29%) 32 (57%)
aStrong: strong staining in >10% of tumour cells; intermediate: positive staining in
p10% of tumour cells or weak and diffuse positive staining; negative: no staining.
A
B
Figure 1 Immunohistochemical staining on paraffin-embedded speci-
mens of testicular germ-cell tumours. (A) ( 100) BCRP strong positive
embryonal carcinoma stained with MAb BXP-21. Note the strong diffuse
membranous and cytoplasmic staining pattern. (B) ( 200) LRP strong
positive choriocarcinoma stained with MAb LRP. Note the strong granular
cytoplasmic pattern in syncytiotrophoblastic cell.
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MDR status and response to induction chemotherapy
Regardless of the grouping of the intermediate category, no
significant association was observed between the expression of
Pgp, MRP1, BCRP, and LRP and the response to induction
chemotherapy (Table 4).
MDR status and clinical outcome
Three-year PFS for all 56 patients included in the survival analysis
was 85.3% (95% CI, 75.2–95.3%), and 3-year OS 91.4% (83.9–
99.4%). With seven relapses and four cancer-related deaths,
median PFS and OS have not been reached. Regardless of the
grouping of the intermediate category, no association was
observed for Pgp, MRP1, and BCRP expressions either with PFS
(strong vs intermediate/negative: P¼ 0.307, 0.284, and 0.284,
respectively) or OS (strong vs intermediate/negative: P¼ 0.932,
0.98, and 0.053, respectively). For all three MDR proteins, the
grouping of the strong plus intermediate category resulted in more
unbalanced arms (very few patients in the negative category) and
in lack of significant correlations (data not shown). In contrast,
patients whose tumours showed intermediate or strong expres-
sions of LRP had significantly shorter PFS (P¼ 0.0006; Figure 2A)
and OS (P ¼ 0.0116; Figure 3) than LRP-negative patients. When
considering the three original immunostaining categories sepa-
rately, log-rank statistics for PFS and OS were P¼ 0.0008 and
0.035, respectively (Figure 2B). The grouping of the intermediate
and strong categories discriminated better the outcome according
to LRP expression. By univariate analysis, LRP was the strongest
adverse prognostic marker for PFS (P¼ 0.0006) and OS
(P¼ 0.0116), followed by b-hCG level 45000 IU l1 previous to
induction chemotherapy (P¼ 0.039 for PFS, and P¼ 0.059 for OS).
Risk stratification according to the IGCCC (intermediate-poor vs
good) or RMH (stage IV vs IM–II – III) did not achieve prognostic
significance either for PFS (P¼ 0.07 and 0.481, respectively) or OS
(P¼ 0.138 and 0.38, respectively) in this relatively small set of
patients. As no recurrences or cancer-related deaths (i.e. events)
were accounted among LRP-negative patients, no multivariate Cox
regression analysis could be performed. Instead, we tested survival
distributions for LRP adjusting for statistically related variables
performing a stratified Mantel –Haenszel test. LRP remained
significant after adjusting for b-hCG level (P¼ 0.0029 for PFS,
and P¼ 0.038 for OS), and RMH stage (P¼ 0.001 for PFS, and
P¼ 0.02 for OS).
DISCUSSION
The increasing need of new markers for prediction of response to
chemotherapy and long-term PFS (the most relevant end point for
TGCT patients in prognostic factor analyses), and the scarce data
concerning the expression and significance of MDR-related
proteins in TGCT, prompted us to initiate this study.
The most remarkable finding in our series of advanced TGCT
was that LRP immunoreactivity in pretreatment tumour cells was
prognostic of the clinical outcome. LRP immunostaining, at any
level, was detected in 43% of the patients, consistent with the 50%
previously reported in a short series with only 12 specimens
(Izquierdo et al, 1996b). LRP is the human major protein of
Table 4 Expression of Pgp, MRP1, BCRP, and LRP and response to
induction chemotherapy (n=55 evaluable patients)
n CR (%) CR-S + IR (%) Pa
Pgpb
+ 14 12(86) 2(14) 0.265
 41 39(95) 2(5)
MRP1b
+ 29 26(90) 3(10) 0.613
 26 25(96) 1(4)
BCRPb
+ 47 44(94) 3(6) 0.477
 8 7(87.5) 1(12.5)
LRPb
+ 23 21(91) 2(9) 0.999
 32 30(94) 2(6)
CR=complete response to chemotherapy, CR-S=complete response to chemother-
apy and surgery, IR=incomplete response (see Patients and Methods). aFisher’s exact
test. bPgp+, MRP1+, and BCRP+ represent immunohistochemical category strong;
Pgp-, MRP1-, and BCRP- represent the grouping of intermediate and negative
categories. The grouping of strong and intermediate categories resulted also in not
significant correlations (data not shown) (see Patients and Methods, and Results).
LRP+ represents the grouping of categories intermediate and strong; LRP- represents
negative category. The grouping of intermediate and negative categories resulted also
in not significant correlations (data not shown). For LRP grouping of categories
intermediate and strong is shown due to the prognostic value on PFS and OS (see
Patients and Methods, and Results).
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Figure 2 Progression-free survival according to LRP expression previous
to treatment in 56 patients with advanced testicular germ-cell tumours. (A)
Immunohistochemical categories strong and intermediate (grouped) vs
negative. (B) Considering the three original immunostaining categories
used for scoring (see Patients and Methods, and Results).
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cellular organelles known as vaults (Scheffer et al, 1995; for review,
see Scheffer et al, 2000b), ribonucleoprotein particles with a
peculiar ovoid structure that is highly conserved among various
species. Vaults have been localised in the cytoplasm but also in the
nuclear membrane, probably at the nuclear pore complex
(Chugani et al, 1993). They have been found broadly distributed
in normal human tissues and in tumours (Izquierdo et al, 1996b).
Although vault function is yet undetermined, they are thought to
mediate vesicular and nucleo-cytoplasmic trafficking and trans-
port processes of various substrates including cytostatics (Chugani
et al, 1993; Kitazono et al, 1999). The relevance of LRP as a
constituent of the whole vault particle in the prediction of a MDR
phenotype is well documented in vitro in numerous human cancer
cell lines (Scheper et al, 1993; Izquierdo et al, 1996a; Laurenc¸ot
et al, 1997; Kickhoefer et al, 1998). Kitazono et al (1999) recently
provided the first evidence favouring a causal relation between
vaults and drug resistance. Moreover, basal LRP expression has
been found indicative for cisplatin and carboplatin resistance
(nonclassical MDR-related drugs) in the NCI panel of 61
unselected human tumour cell lines used for drug screening
(Izquierdo et al, 1996a), and in nonsmall-cell lung cancer cell lines
(Berger et al, 2000).
In our study, any extent of LRP immunoreactivity including
strong expression in a minority of cancer cells was associated with
an unfavourable prognosis even after individual log-rank adjust-
ments for statistically related prognostic factors. The strong
biological and clinical rationale supporting the association of
LRP with resistance to a broad spectrum of anticancer drugs,
including cisplatin, and the fact that the two correlations found go
in the same direction (LRP expression correlates with both shorter
PFS and OS), makes unlikely that the positive analyses are due to
multiple subset analysis. The frequent presentation of TGCT as
mixed histologies and the potential significance for prognosis of a
minor component in them make this a unique entity. Our finding
adds to several clinical studies reporting overexpression of LRP at
diagnosis as an independent predictor for clinical outcome and/or
chemotherapy failure, for example, in acute myeloid leukaemia
(List et al, 1996; Borg et al, 1998; Filipits et al, 1998, 2000), multiple
myeloma (Raaijmakers et al, 1998; Filipits et al, 1999), stage III –IV
ovarian carcinoma (Izquierdo et al, 1995), and locally advanced
bladder cancer (Diestra et al, 2001). Other studies have failed to
show prognostic values of LRP immunoreactivity in acute
leukaemia (Damiani et al, 1998; Leith et al, 1999) and ovarian
carcinoma (Arts et al, 1999). Despite the prognostic value of LRP
in this study, no relation was observed between LRP expression
and response to platinum-based chemotherapy. Whether this lack
of correlation was because of the very high rate of CR observed
(93%, otherwise expected in TGCT) in our relatively small series of
patients remains uncertain. As an alternative explanation, LRP
may be a marker of biological aggressiveness in TGCT. This is
suggested not only by the fact of poorer clinical outcomes for
patients with LRP-expressing tumours, but also by the observed
correlation between LRP and well-known factors conferring bad
prognosis such as high b-hCG levels and visceral metastatic
disease. Baldini et al (1995) found a similar conclusion for Pgp in
high-grade osteosarcomas. They reported a strong correlation
between the presence of increased levels of Pgp at diagnosis and
bad prognosis that was unrelated to response to chemotherapy. We
cannot exclude a potential influence of the histological subtype
CC over the observed LRP value for prognosis in our series, as
all of the CC elements stained for LRP (and b-hCG is elaborated
by syncytiotrophoblastic components in CC). However, most
prognostic classifications have failed to identify any particular
histology as an independent variable for outcome (Mead
et al, 1992). More detailed studies on the relation of LRP
with clinicopathological parameters in TGCT are therefore
warranted.
Pgp expression was observed in 27% of tumours, in agreement
with previous reports (35%, Katagiri et al, 1993; 33%, Eid et al,
1998). In contrast to the report by Eid et al (1998), we found no
association between Pgp expression and nonseminomatous
histology or advanced stages of disease. This discrepancy can be
attributed to our small number of seminomas and the use of
different methodologies for Pgp detection. In agreement with the
previous study, Pgp expression did not predict response to
chemotherapy and was not related to survival. Neither in vitro
nor clinical data suggest a relation between Pgp expression and
resistance to cisplatin. However, the incorporation of etoposide, a
substrate for Pgp (Germann, 1996), into combination chemother-
apy regimens has improved response rates and long-term survival
of poor-risk TGCT patients (Bosl and Motzer, 1997; Sonneveld
et al, 2001). Whether the expression of Pgp in TGCT influences
response to chemotherapy and outcome after regimens containing
etoposide needs to be investigated in a much larger group of
patients primarily treated with this drug.
There is only one previous study concerning MRP1 expression
in TGCT (Eid et al, 2000). We report MRP1 overexpression in
54% TGCT, whereas Eid et al (2000) reported in 100% using a
different MAb but similar criteria for assessment. In our study,
MRP1 expression did not predict response to chemotherapy or
outcome. All attempts to demonstrate MRP1 as a mediator of
cisplatin resistance have failed thus far; although MRP1 is involved
in efflux conjugates of drugs to glutathione (one of the cellular
thiol compounds involved in resistance to platinum agents;
Borst et al, 2000). Eid et al (2000) reported MRP1 expression in
the nucleus, in accordance with our observation, an intriguing
binding of unclear significance. They speculated about a possible
role for MRP1 unique to TGCT in the intracellular redistribution of
drugs. However, we cannot exclude this finding being a staining
artefact.
Recently, the novel ATP-dependent transporter BCRP was
identified in mitoxantrone-selected MDR cell lines not expressing
Pgp or MRP1 (Allikmets et al, 1998; Doyle et al, 1998). Thus far,
BCRP has been described in cancer cell lines of different
histogenetic origin (Scheffer et al, 2000a). Additionally, expression
of BCRP has been reported in normal human tissues (Maliepaard
et al, 2001), in a small panel of human tumour samples including
two seminoma specimens (both considered BCRP-negative;
Scheffer et al, 2000a), and in human breast carcinoma (Kanzaki
et al, 2001) and acute leukaemia (Ross et al, 2000). We report
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Figure 3 Overall survival according to LRP expression previous to
treatment in 56 patients with advanced testicular germ-cell tumours.
Immunohistochemical categories: strong and intermediate (grouped) vs
negative.
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BCRP overexpression in 86% of TGCT, particularly in EC and
in syncytiotrophoblasts in CC. The high expression rate of BCRP in
placental syncytiotrophoblast (Maliepaard et al, 2001) is therefore
retained in its malignant counterpart. BCRP did not predict
response to chemotherapy and was not related to survival,
consistent with its wide expression in TGCT and the limited
role in this disease of the cytostatics to which BCRP confers
resistance. In particular, BCRP is not involved in resistance to
cisplatin (Allikmets et al, 1998; Doyle et al, 1998; Maliepaard et al,
1999).
In conclusion, our data suggest that the expression of LRP at the
time of diagnosis of a metastatic TGCT may identify a patient
population with a tendency to progress despite chemotherapy. The
adverse prognostic value of LRP may be important because it may
influence early selection of TGCT patients for novel therapeutic
strategies. Moreover, the search for pharmacological agents
capable of affecting vault function might also help in optimising
treatment protocols in the future. However, because of the limited
number of patients in this study, our results must be interpreted
with caution. Whether LRP will increase the predictive power of
current clinically oriented prognostic models remains to be
determined in larger, prospective studies. The intriguing hypoth-
esis derived from our study may prompt the initiation of such
studies by institutions or collaborative groups capable of recruit-
ing a large number of cases of this relatively rare type of cancer.
We strongly encourage confirmation or rebuttal of our findings
(especially the zero cell) by others.
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